Please login to the form below

Not currently logged in
Email:
Password:

Sanofi/Rib-X antibiotic collaboration

Sanofi has announced it is to partner with Rib-X Pharmaceuticals to research new classes of antibiotic therapies

Sanofi has announced it is to partner with Rib-X Pharmaceuticals to research new classes of antibiotic therapies.

The deal will see Rib-X receive a $10m upfront payment, with the potential for a further $9m in near-term research-based milestones as well as future regulatory and commercial milestsones.

According to Sanofi, the agreement could result in up to $186m in total milestone payments for Rib-X on a per product basis.

In return, Sanofi will hold the licence to any assets developed using Rib-X's RX-04 programme as part of the deal, with Sanofi able to develop multiple products.

The RX-04 programme is used to develop antibiotics for the treatment of Gram-negative and Gram-positive pathogens, and has shown success in treating multi-drug resistant strains.

"The clinical need for new antibiotics is reaching crisis level, yet the antibiotic pipeline is running dry and fewer and fewer companies are working to develop drugs in this space," said Dr Elias Zerhouni, president, global research and development at Sanofi. "This partnership exemplifies Sanofi's commitment to translate novel approaches for treatment into patient solutions addressing the global critical need to combat the rising threat of antibiotic drug resistance."

6th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics